Cero Therapeutics Holdings, Inc. 8-K Report Overview - January 2025 Insights
Based on the provided section of the financial report, here are the key insights and information extracted:
- Company Information:
- Name: Cero Therapeutics Holdings, Inc.
- CIK: 0001870404
- Address: 201 Haskins Way Suite 230, South San Francisco, CA 94080
- Contact Number: 650-407-2376
- Trading Symbols:
- Common Stock: CERO (NASDAQ)
- Warrants: CEROW (NASDAQ)
- Filing Type and Date:
- Filing Type: 8-K
- Filing Date: January 6, 2025
- Stock Information:
- Common Stock:
- Par Value: $0.0001 per share
- Warrants: Each whole warrant is exercisable for one share of common stock.
- Reporting Period:
- The report covers a specific date of January 6, 2025. This indicates a snapshot of the company’s financial position or significant events as of this date.
- Units of Measure:
- Financial figures are reported in USD (United States Dollars).
- Share-related metrics are reported in shares.
- Contextual Information:
- The report includes explicit member dimensions indicating classifications of stock, specifically pertaining to common stock and warrants.
Insights:
- The information indicates that Cero Therapeutics is actively reporting its financial status or significant developments as of early January 2025, which could be relevant for investors and stakeholders monitoring the company.
- The low par value of common stock ($0.0001) suggests the company may be in a growth phase, possibly appealing to investors looking for opportunities in emerging biotech or therapeutics.
- The mention of warrants indicates potential future dilution of shares if these are exercised, which is a critical factor for current shareholders to consider.
This summary encapsulates the entity's relevant details and context provided in the XML snippet from the financial report.